Images List Premium Download Classic

Prostate Cancer

Prostate Cancer-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
The Regents Of The University Of California
August 17, 2017 - N°20170233488

This invention provides a method that allows selection of antibodies against cells (e. G., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.
Combination methods for immunotherapy
The Regents Of The University Of California
August 17, 2017 - N°20170232070

The present invention includes a method of treating prostate cancer in a human subject in need thereof, comprising administering to the subject an effective amount of a composition comprising interleukin-2 (il2), and administering to the subject a cell expressing a chimeric antigen receptor (car) which specifically binds prostate specific membrane antigen (psma), thereby treating prostate cancer in the human subject ...
System and method for diagnosis and treatment
Pop Test Oncology Limited Liability Company
August 17, 2017 - N°20170232005

This invention relates the use of cortisol blockers (glucocorticoid receptor [gr] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
Prostate Cancer Patent Pack
Download 215+ patent application PDFs
Prostate Cancer Patent Applications
Download 215+ Prostate Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Prostate Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compounds for treatment of cancer
University Of Tennessee Research Foundation
August 10, 2017 - N°20170226086

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e. G. Melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
Anti-alpha-v integrin antibody for the treatment of prostate cancer
Merck Patent Gmbh
August 03, 2017 - N°20170218070

The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (crpc), optionally accompanied by lymph node and bone tissue metastases (mcrpc). In particular, the invention relates to the therapy of said patients ...
Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase ...
Wayne State University
August 03, 2017 - N°20170217903

A novel class of drugs for treating androgen receptor (ar) positive cancer including prostate cancer and breast cancer are described. The drugs include the chemical scaffolds of a high affinity androgen receptor ligand and a histone deacetylase inhibitor. Also described are compositions including the novel drugs and methods of treating ar positive cancer using the compositions.
Prostate Cancer Patent Pack
Download 215+ patent application PDFs
Prostate Cancer Patent Applications
Download 215+ Prostate Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Prostate Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Abiraterone derivatives and non-covalent complexes with albumin
Fl Therapeutics Llc
August 03, 2017 - N°20170216443

The present disclosure provides derivatives of abiraterone, non-covalently bound complexes of the abiraterone derivatives with serum albumin, pharmaceutical compositions of the same, and methods of use thereof. The non-covalently bound complexes are significantly more water-soluble than abiraterone and are useful for the treatment of a disease or condition that can benefit from cyp17 inhibition, such as prostate cancer.
Combination therapies and methods of use thereof for treating cancer
Massachusetts Institute Of Technology
August 03, 2017 - N°20170216317

Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than ...
Substituted phenyl aziridine precursor analogs for inhibiting androgen-independent prostate cancer cell growth
Northwestern University
August 03, 2017 - N°20170216249

Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include one or more substituted phenyl aziridine precursors, their respective aziridines, analogs thereof, derivatives thereof, or pharmaceutically acceptable salts thereof such as cpda. The methods and compositions may be used for treating diseases, disorders, and conditions associated ...
Dual ionophore ion selective electrode for detecting non-ionic molecules, macromolecules and cells
Washington State University
July 27, 2017 - N°20170212118

Biosensor and method of using the biosensors for the detection of prostate cancer are provided. The biosensors include a dual ionophore ion selective electrode for detecting very low levels of prostate cancer antigens at early stages of prostate cancer development.
Algorithmic approach for determining the plasma genome abnormality pga and the urine genome abnormality uga ...
Mayo Foundation For Medical Education And Research, A Charitable Corporation Of Minnesota
July 27, 2017 - N°20170211153

The present invention relates to methods of using cell-free dna analysis for guiding treatment of advanced prostate cancer. In particular, liquid biopsies are collected from urine and/or plasma of patients for measuring copy number variation in cell-free dna associated with metastatic prostate cancer. In particular, urine genomic abnormality (uga) and plasma genomic abnormality (pga) values are contemplated for use ...
Biomarkers for pin1-associated disorders
Beth Israel Deaconess Medical Center, Inc.
July 20, 2017 - N°20170204466

Biomarkers and driver mutations for diagnosis and prognosis of pin 1-associated diseases are disclosed. In one embodiment, the methods for diagnosis of pin 1-associated diseases may include detecting the level of pin1 to stage abnormal cell growth, such as breast or prostate cancer. In another embodiment, the methods include evaluating the efficacy of a treatment of abnormal cell growth, such ...
Conjugates for immunotherapy
University Of South Florida
July 20, 2017 - N°20170202902

The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a t cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the ...
Prostate Cancer Patent Pack
Download 215+ patent application PDFs
Prostate Cancer Patent Applications
Download 215+ Prostate Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Prostate Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Prostate cancer screening module and method for operating the same
Chang Gung University
July 13, 2017 - N°20170199146

The present invention relates to a prostate screening module and the method for operating the same. It uses nanometer-grade nickel oxide as the screening film. By contacting nickel oxide with hydrogen peroxide having various concentrations, the surface potential of nickel oxide will be changed and resulting in voltage shift, which can be used to judge the concentration of hydrogen peroxide. ...
Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination ...
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
July 13, 2017 - N°20170198352

The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining ...
Single cell-derived organoids
Rutgers, The State University Of New Jersey
July 13, 2017 - N°20170198261

The present invention relates to organoids derived from a single cell, such as a prostate cancer cell, and methods and compositions relating to the production and use thereof, including cell culture medium for producing organoids and methods of personalized treatment for prostate cancer. The invention further provides a humanized mouse comprising a prostate organoid derived from a patient's prostate cell.
Recombinant t cell receptor ligand compositions and methods for treatment of prostate cancer
University Of Maryland, Baltimore
July 13, 2017 - N°20170196957

Disclosed herein are compositions and methods for treating or inhibiting prostate cancer. The compositions include a mhc molecule including covalently linked first and second domains, wherein the first domain is an mhc class ii β1 domain and the second domain is an mhc class ii α1 domain, wherein the amino terminus of the α1 domain is covalently ...
Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer
Ab Science
July 13, 2017 - N°20170196853

A treatment of patients afflicted with prostate cancer, wherein the treatment includes administering to a mammal in need thereof at least one tyrosine kinase inhibitor or mast cell inhibitor that is an inhibitor of kinase activity selected from the tyrosine kinases of: c-kit, pdgfr, lyn, fyn, or any combination thereof, in particular masitinib, optionally in combination with at least one ...
Methods and compositions for determining resistance to androgen receptor therapy
Aragon Pharmaceuticals, Inc.
July 13, 2017 - N°20170196840

Described herein are modified androgen receptor polypeptides that are resistant to inhibition by an androgen receptor inhibitor. Described herein are compositions, combinations, and kits containing the modified androgen receptor polypeptides and methods of using the modified androgen receptor polypeptides. Also described herein are methods of using the modified androgen receptor polypeptides as screening agents for the identification and design of ...
Sequence variants associated with prostate specific antigen levels
Decode Genetics Ehf
July 06, 2017 - N°20170191134

Certain sequence variants have been found to be useful for correcting prostate specific antigen levels in humans. The invention provides diagnostic applications based on such correction, including methods of diagnosis of prostate cancer.
Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
Genomedx Biosciences, Inc.
July 06, 2017 - N°20170191133

A system for expression-based discrimination of distinct clinical disease states in prostate cancer is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated with recurrent or non-recurrent prostate cancer. The prostate cancer prognostic system provides for ...
Loading